Phase I/II – First Administration

454 trials 191 recruiting

Filter these 454 trials by condition, country, sponsor and more.

Open in Search →

A Phase I/II First-In-Human Clinical Trial to Evaluate the Safety, Tolerability and Anti-Tumor Activity of IMA402, a Bispecific T Cell-Engag… Recruiting

2022-503133-54-00 Solid Tumors 2023-08-09
A Phase 1/2 Open Label non randomized Study, multicentric, single arm evaluating the Safety and Efficacy of Gene Therapy of the severe comb… Recruiting

2024-513652-15-00 Severe Combined Immuno-Deficiency (SCID) caused by bial 2023-07-19
A phase 1/2 open-label, multicenter study to assess the safety, pharmacokinetics and anti-tumor activity of GTAEXS617 in patients with advan… Recruiting

2023-508227-13-00 Advanced solid tumors 2023-06-19
Early phase study to evaluate the safety and efficacy of SMART101 to improve transplantation in blood cancers Recruiting

2024-517953-28-00 Treatment in haematopoietic stem cell transplantation 2023-06-07
Phase 1/2 multicenter, open-label, dose-escalation study of IDP-121 in patients with relapsed/refractory hematologic malignancies (CASSANDRA… Recruiting

2024-519194-19-00 Any type of B-cell lymphomas 2023-06-06
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in R/R PCNSL Recruiting

2024-513312-95-00 Part B+C. Primary central nervous system lymphoma (PCNS 2023-05-30
A first-in-human clinical study of PBP1510 in patients with pancreatic cancer. Recruiting

2024-514379-16-00 Advanced and/or metastatic pancreatic adenocarcinoma 2023-04-01
Phase I/Ib clinical trial of PM54 in Advance Solid Tumors patients Recruiting

2023-508644-22-00 Advance Solid Tumors 2023-02-28
Phase I trial evaluating the tolerance of repeated opening of the bloodbrain barrier by ultrasound before chemotherapy in the treatment of r… Recruiting

2024-516169-35-00 recurrent primary supratentorial malignant brain tumors 2023-02-06
A phase 1/2a, open-label trial to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple ascending doses o… Recruiting

2024-514328-18-00 Spinocerebellar ataxia types 1, 3 and Huntington's dise 2022-12-06
A multicenter phase 1/2 study of OSE-279, a PD-1 blocking monoclonal antibody, in subjects with advanced solid tumors or lymphomas Recruiting

2024-514826-22-00 Part A: Patients with advanced solid tumors or lymphoma 2022-12-05
Phase I Study of PM534 Administered to Patients with Advanced Solid Tumors Recruiting

2024-513056-15-00 Advanced Solid Tumors 2022-12-01
A Phase 1/2 Study of the Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor NVL-655 in Patients with Advanced NSCLC and Other Solid Tumors… Recruiting

2024-514266-39-00 Advanced Non-Small Cell Lung Cancer (NSCLC) and Other S 2022-11-03
Clinical trial of infusion of activated NK cells for the treatment of children, adolescents and young adults with sarcomas. Recruiting

2024-513431-25-00 Sarcomas 2022-10-18
Study of AZD9574 as monotherapy and in combination with anti-cancer agents in patients with advanced solid malignancies Recruiting

2023-504984-17-00 Module 3: advanced/relapsed HER2-negative breast, ovari 2022-10-05
Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C) Recruiting

2022-502756-31-00 KRAS G12C-Mutant Advanced Solid Tumors 2022-07-20
A study to investigate the short- and long-term safety and tolerability of the drug SNDX-5613 in Patients with Relapsed/Refractory Leukemias… Recruiting

2024-513759-34-00 Relapsed or Refractory Acute Leukemias 2022-05-31
A Phase 1/2 Study of BMS-986340 with and without Nivolumab or Docetaxel in Solid Tumors Recruiting

2023-503651-10-00 Male and female participants ≥ 18 years of age with adv 2022-05-17
Phase 1/2 study of IMC-M113V in virologically suppressed chronic HIV infection Recruiting

2024-513938-38-00 Chronic HIV infection 2022-04-06
A randomised, double blind clinical trial investigating the safety and tolerability of multiple increasing doses of EDV2209 compared to plac… Recruiting

2024-514590-22-00 Subarachnoid haemorrhage – SAH 2022-03-10
A Phase 1/2 Study of the Highly Selective ROS1 Inhibitor NVL-520 in Patients with Advanced NSCLC and Other Solid Tumors (ARROS-1) Recruiting

2024-511793-71-00 Advanced ROS1-positive NSCLC and other advanced ROS1-po 2022-02-28
DZR123 (CPI-0209) in Patients with Advanced Solid Tumors and Lymphomas Recruiting

2023-508002-20-00 advanced, solid, relapsed tumors / advanced tumors: hum 2021-10-21
A Phase 1/2a, First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of HDP-101 in Patients with Plasma C… Recruiting

2024-515273-10-00 Relapsed or refractory Multiple Myeloma (r/r MM) 2021-10-19
A Phase 1/2 Trial of the Synthetic Cannabinoid ART27.13 in Patients with Cancer Anorexia and Weight Loss Recruiting

2024-518177-33-00 Cancer Anorexia 2021-10-01